Radiation therapy for multiple myeloma: treating painful lesions and protecting function

A recommendation to irradiate one painful site does not necessarily mean that a patient's systemic myeloma treatment has failed. Radiation may address a lesion that remains troublesome while medicines control disease elsewhere. It may also be needed when a mass threatens nerves or when a particular area progresses after previous treatment. The useful starting point is the intended local benefit: pain relief, tumor control or protection of function. Information was checked in September 2026 for patients considering hematology and radiation-oncology assessment in China.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Multiple myeloma generally requires systemic treatment because abnormal plasma cells are not confined to the irradiated area. Treating a rib, vertebra or soft-tissue mass does not automatically control disease throughout the marrow. Local radiation can relieve symptoms and control a selected lesion while the hematologist manages the wider illness. Feeling less pain in the treated area is therefore not a reason to stop systemic medicines independently. The ILROG guideline for plasma-cell neoplasms distinguishes the local roles of radiation in myeloma and solitary plasmacytoma.
Radiation techniques seek to deliver the prescribed dose to the target while limiting exposure of nearby tissues. A lesion next to the spinal cord, a previously treated region or a complex-shaped mass may require particularly careful planning. The team should explain what a proposed technology changes in the dose distribution and what patient benefit is expected.
Previous radiation to the same region makes the original plan particularly important. Obtain dose distributions, treatment dates, fraction details and the completion summary. A note saying that ten treatments were given is insufficient to judge another course. The new team must understand exposure of the spinal cord, bowel or other nearby organs, and retrieving those files may take time.

Quick answer

Full guide

Establish whether the diagnosis is myeloma or a solitary plasmacytoma

Multiple myeloma generally requires systemic treatment because abnormal plasma cells are not confined to the irradiated area. Treating a rib, vertebra or soft-tissue mass does not automatically control disease throughout the marrow. Local radiation can relieve symptoms and control a selected lesion while the hematologist manages the wider illness. Feeling less pain in the treated area is therefore not a reason to stop systemic medicines independently. The ILROG guideline for plasma-cell neoplasms distinguishes the local roles of radiation in myeloma and solitary plasmacytoma.

For a true solitary plasmacytoma, definitive radiation may be the principal treatment. However, seeing a single mass on one scan is insufficient to establish that diagnosis. Marrow assessment, blood and urine studies and appropriate whole-body imaging are needed to exclude systemic disease. The 2026 IMWG recommendations for solitary plasmacytoma emphasize this distinction and state that the clinical benefit of systemic treatment in this setting remains incompletely defined. Follow-up remains necessary after successful local treatment because additional disease can emerge later.

Ask that the diagnosis and treatment intent appear explicitly in the consultation note. A quotation or appointment request that simply says “plasma-cell tumor radiation” can obscure a major difference in planning. If staging is incomplete, the team should identify which missing result could change the proposed course.

Describe what brings on the pain

Persistent pain arising from a local myeloma lesion may improve with radiation. Pain that becomes markedly worse on standing, turning or bearing weight also raises concern about fracture or structural instability. Record where it hurts, which movements provoke it, whether it wakes you at night, the pain medicines required and how far you can walk. This information helps distinguish a symptom that may respond to tumor control from a mechanical problem requiring a different intervention.

Radiation does not immediately restore the strength of a damaged bone. An unstable vertebra or a weakened weight-bearing bone may need orthopedic or spinal assessment before treatment. The IMWG bone-disease recommendations address the complementary roles of bone-targeted medicines, radiotherapy and orthopedic procedures. Relief of pain should not be interpreted as confirmation that a fracture has healed or that unrestricted exercise is safe.

Patients should receive specific instructions for weight-bearing and transfers when structural risk is present. A general recommendation to stay active may need adaptation to the affected bone. Tell the team about falls, difficulty getting out of bed and whether the home environment contains stairs, because these details influence rehabilitation and discharge planning.

New neurological symptoms require urgent assessment

Back pain accompanied by new leg weakness, difficulty walking, sensory loss, saddle-area numbness or bladder or bowel dysfunction can indicate spinal cord or cauda equina compression. Seek urgent local medical care rather than waiting for an international consultation or a routine follow-up scan. The clinical examination and imaging must establish both the compression and any instability.

Myeloma is radiosensitive, but that does not mean radiation alone resolves every spinal emergency. Bone fragments, collapse or substantial instability can require surgical assessment. The sequence of corticosteroids, radiation, surgery and systemic treatment should be decided by the relevant teams. NICE guidance on spinal disease and cord compression also applies to direct malignant infiltration of the spine and emphasizes rapid imaging and coordinated care.

A prospective appointment in China cannot substitute for emergency stabilization where the patient currently is. Once the immediate problem is managed, records of the neurological examination, imaging and treatment decisions will help another center assess continuing care. Families should not attempt to test a patient's walking ability repeatedly when clinicians have advised spinal precautions.

Planning images answer a different question from staging images

The hematologist's imaging assesses the distribution and behavior of myeloma. The radiation team's planning scan defines how treatment can be delivered safely to a particular area. CT depicts bone destruction and structure; MRI provides information about marrow and soft tissues around neural structures; PET/CT can help characterize metabolically active lesions. These methods are complementary rather than automatically redundant. The IMWG imaging consensus explains their respective clinical uses.

Bring readable original images as well as reports. Photographs of a few printed slices generally cannot support detailed treatment planning. Images obtained before a lesion shrank on systemic therapy may also be useful in understanding its original extent. If the appearance or diagnosis of a mass is uncertain, pathology may be needed when it would alter treatment intent.

Before accepting an additional scan, ask what decision it will inform and whether recent usable imaging already answers that question. This is especially helpful for international patients whose investigations have been performed in several hospitals. Avoid assuming that every repeat study is unnecessary, or that a very recent report eliminates the need for radiation simulation.

The number of treatments depends on the local objective

A short course for pain relief, treatment of a compressive lesion and definitive treatment of a solitary plasmacytoma do not share one universal schedule. Size, site, soft-tissue extension, previous irradiation, marrow reserve and the desired duration of control influence the prescription. Ask for the total dose, dose per treatment and number of fractions rather than relying on the appointment count alone.

The 2024 ASTRO guideline on palliative radiation for symptomatic bone lesions provides evidence for several approaches in metastatic bone disease. Its findings should not be transferred indiscriminately to every plasma-cell tumor. Myeloma-specific guidance and the individual lesion remain important. Fewer visits may reduce travel burden, while other circumstances require a different schedule; neither a longer nor a shorter course is inherently a measure of treatment quality.

For a patient traveling to China, ask how many separate planning, treatment and review visits are anticipated. A schedule quoted as a certain number of fractions may omit the interval needed for simulation and plan preparation. Clinical urgency should determine the timetable before accommodation or return flights are finalized.

Choose a technique for a defined reason

Radiation techniques seek to deliver the prescribed dose to the target while limiting exposure of nearby tissues. A lesion next to the spinal cord, a previously treated region or a complex-shaped mass may require particularly careful planning. The team should explain what a proposed technology changes in the dose distribution and what patient benefit is expected.

Equipment names such as proton therapy or a branded stereotactic platform should not by themselves determine an international referral. Ask whether a conventional approach can already meet the treatment goal, which risk a more complex technique is expected to reduce, and whether waiting for that service is clinically acceptable. The National Cancer Institute's external-beam explanation describes planning and positioning. Ordinary external-beam treatment does not make the patient radioactive afterward.

If lying in the required position is painful, tell the team before simulation. Analgesia and positioning arrangements may be needed to make a reproducible plan possible. Report implanted devices and previous operations, and provide their details when requested. The practical ability to complete each treatment matters alongside the theoretical advantages of a machine.

Cement augmentation and fixation address structural problems

Selected painful vertebral compression fractures may be treated with vertebroplasty or balloon kyphoplasty. Suitability depends on the pain source, fracture anatomy, neural structures and factors such as infection and coagulation status. Cement augmentation can stabilize an appropriate fracture but does not treat all marrow disease or replace decompression for every neurological problem. The IMWG consensus on vertebral cement augmentation discusses patient selection and timing.

The hematologist, radiation oncologist and procedural or spinal team should agree on the order of interventions. Existing screws, cement or other implanted material should be documented for the planning team. Patients need instructions on turning in bed, sitting, walking and rehabilitation, rather than only a statement that the tumor has become smaller.

A combined plan may involve distinct goals: systemic therapy to reduce disease activity, a procedure to stabilize a fracture and radiation to control a local lesion. Ask who is responsible for reviewing each goal. A reduction in pain does not automatically establish that every component of the plan can be cancelled.

Discuss stem-cell collection and concurrent medicines before radiation starts

Patients considering autologous stem-cell collection should tell the radiation oncologist early. Irradiation can affect the success of collection in some circumstances, so treatment fields and timing should be discussed with the hematology team; NICE specifically highlights this issue. Urgent protection of neurological function must not be delayed simply to preserve a preferred collection calendar, but the competing priorities should be documented.

Decisions about holding or continuing systemic medicines depend on the actual drug, treatment area and expected toxicity. Marrow suppression and overlapping effects require coordinated review. The EHA–EMN myeloma guideline provides the broader treatment context. Patients should neither stop all their medicines independently nor assume that a small local field makes coordination unnecessary.

Keep a current list of treatment dates, blood counts and planned procedures. When several departments are involved, ask which clinician will reconcile changes to the schedule. A discharge sheet from one department may not contain the complete systemic-treatment plan.

Assess benefit through pain, function and local control

Pain relief may not occur after the first fraction. Follow-up should examine pain intensity, analgesic requirements and practical activities rather than expecting an immediate visible change in the bone. Continuing to need pain medicine early does not by itself prove failure. Sudden worsening or new neurological symptoms requires reassessment instead of simply waiting for the next booked review.

Systemic blood markers can continue to reflect disease outside the irradiated site, while structural bone defects may remain visible after successful local treatment. These are different aspects of response. NICE myeloma recommendations include continuing bone and disease assessment. Bring the pretreatment symptom record to make improvement easier to judge, and avoid abruptly stopping analgesia or increasing weight-bearing to test whether radiation worked.

Ask what symptoms should lead to a same-day call, when routine review is planned and which imaging will be meaningful at that time. The return of pain may have several explanations, including fracture, treatment effects or active disease, and should not automatically be labeled recurrent tumor without evaluation.

Prepare the information needed for treatment in China

Previous radiation to the same region makes the original plan particularly important. Obtain dose distributions, treatment dates, fraction details and the completion summary. A note saying that ten treatments were given is insufficient to judge another course. The new team must understand exposure of the spinal cord, bowel or other nearby organs, and retrieving those files may take time.

Request an itemized RMB quotation stating whether consultation, simulation CT, immobilization, planning, delivery, image verification and review are included. Admission, spinal surgery, rehabilitation and systemic medicines should be identified separately when relevant. Without the treated site, proposed technique and hospital quotation, a uniform price would be unreliable. Two estimates with the same fraction count may cover different services.

Before return travel, review pain control, safe transfers, mobility support and the need for an accompanying person. The final radiation appointment is not necessarily the end of fracture recovery or systemic-treatment planning. Leave with the radiation summary, plan files, activity restrictions and contact instructions so that the home team can continue both skeletal and myeloma care.